Early Warning Report News Release
May 17 2024 - 7:47PM
Michael Dalsin has filed an early warning
report (the “
Report”) regarding his holdings in
Evome Medical Technologies Inc. (the “
Issuer”).
Pursuant to the Issuer’s Annual Report on Form
10-K for the fiscal year ended December 31, 2023, which was
filed by the Issuer with securities regulators on April 16, 2024,
the Issuer disclosed that it had 21,056,409 Class “A” non-voting
common shares (the “Class A Shares”) issued and
outstanding as of April 9, 2024. As a result, as of at least April
9, 2024, Michael Dalsin ceased to hold at least 10% of the Class
A Shares.
Accordingly, as of at least April 9, 2024, the
Michael Dalsin’s securityholdings and percentage in the Class A
Shares decreased from 755,425 (55.7%) to 755,425 (3.6%) on both a
non-diluted and partially diluted basis, and Mr. Dalsin has filed
an early warning report (Form 62-103F1).
Mr. Dalsin may increase or reduce his investment
in the Issuer according to market conditions or other relevant
factors.
For further details relating to the acquisition,
please see the Report, which was filed in accordance with
applicable securities laws, a copy of which is available under the
Issuer’s profile on the SEDAR+ website at www.sedarplus.com, or may
be obtained from Mr. Dalsin by contacting 646-450-3119.